This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

The U.S. FDA-approved Iron (III) Isomaltoside for neurological disorders on January 16, 2020. Iron (III) Isomaltoside belongs to the medication class known as anti-anemic medicines. 

Mechanism of Action of undefined

Iron (III) Isomaltoside restores the iron in the body, which helps to improve red blood cell production and increase hemoglobin levels. This leads to a reduction in anemia symptoms such as fatigue, weakness, and shortness of breath, ultimately improving the overall well-being and quality of life of the patient.

Uses of undefined

Iron (III) Isomaltoside is used as an iron replacement medicine to treat iron deficiency anemia in adults who are intolerant to oral iron or have not responded well to oral iron preparations. Additionally, this medication treats this condition in individuals with chronic kidney disease who are on dialysis and cannot take oral iron supplementation.

undefined Drug administaration and Dosage available

Iron (III) Isomaltoside will be administered to you by a healthcare professional in a hospital setting. It is usually administered in a vein (intravenous) or into the dialyzer. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.

Warnings, Precautions and Side Effects of undefined


Iron (III) Isomaltoside should not be consumed if you are allergic to Iron (III) Isomaltoside or any of its ingredients in the medication. Do not take this medicine if the anemia was not caused by iron deficiency (such as "hemolytic" anemia), or if you have iron overload or impaired iron utilization in the body if you have a history of severe allergic reactions to other injectable iron preparations and active liver disease. Due to limited data on safety and efficacy, Iron (III) Isomaltoside is not recommended for use in individuals under the age of 18, including children and adolescents.


Notify your doctor if you are pregnant, planning to get pregnant, or think you may be pregnant or breastfeeding. Before receiving Iron (III) Isomaltoside, it is important to inform your doctor if you have a history of medicine allergy, systemic lupus erythematosus, rheumatoid arthritis, or severe asthma. Notify your doctor if you have eczema, or other allergies, an ongoing bacterial infection in your blood, or reduced liver function.

Side Effects

The most common side effects of Iron (III) Isomaltoside are rash and nausea. Serious side effects while taking Iron (III) Isomaltoside are severe allergic reactions (rash, itching, dizziness, low blood pressure, breathing problems), and iron overload. 

Word Of Advice

Liver patients should take Iron (III) Isomaltoside cautiously and inform their doctor about all the underlying medical conditions. Do not stop the medicine until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Do not breastfeed while taking Iron (III) Isomaltoside unless your doctor advises. Notify your doctor if you experience any serious side effects. Contact your doctor for more information. Contact your doctor for more information. Keep out of sight and reach of pets and children. Do not freeze the medicine. Do not store above 30°C. Always check the expiry date before consuming it.

Frequently Asked Question


  1. Pharmacosmos A/S, Electronic Medicines Compendium (EMC), [Revised on January 2023] [Accessed on 21st June 2023], *pil.13404.pdf (
  2. Pharmacosmos A/S, US Food, and Drug Administration, [ Revised on Jan 2020] [ Accessed on 21st June 2023],
  3. Thomas AR Mace, Ahsan Syed, Sunil Bhandari; Iron (III) isomaltoside 1000; Expert Review of Hematology; Published on June 2013; 21st June 2023;


The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.